Cancer Metabolism

Genetic alterations and epigenetic modifications of cancer cells result in cellular metabolic pathways that are different in comparison to normal cells. Due to the inherent genetic instability of cancer cells, tumors are heterogeneous with a myriad microenvironments and multiple altered metabolic pathways, which could provide useful cancer therapeutic targets.

Cancer Metabolism Products Targets

Products for Cancer Metabolism

Cat.No. Product Name Information/Activity
BCC4097 BMS-303141 BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
BCC7956 MEDICA 16 87272-20-6
BCC6342 SB 204990 SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
BCC2314 Topiramate Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
BCC2312 U-104 U-104 is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM; low inhibition for CA I and CA II.
BCC2301 Methotrexate Methotrexate (Amethopterin) is an antimetabolite and antifolate agent that inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate (Amethopterin) is the disease-modifying antirheumatic drug (DMARD) of first choice for the treatment of RA in most countries worldwide. Methotrexate is an antineoplastic agent used to fight a number of different cancers, such as acute lymphoblastic leukemia and solid cancers.
BCC2307 Pyrimethamine Pyrimethamine(RP4753) is a medication used for protozoal infections; interferes with tetrahydrofolic acid synthesis from folic acid by inhibiting the enzyme dihydrofolate reductase (DHFR).
BCC2386 C 75 trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.
BCC8053 GSK2194069 GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM in an assay detecting released CoA.
BCC3830 Orlistat Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.